Recently, Sacituzumab-TMT (MK-2870/SKB264), a next-generation TROP2-targeting ADC, demonstrated superior PFS compared to docetaxel in previously treated EGFR-mutant NSCLC patients, the first ADC to do so in this setting [30]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.